AU2015342969B2 - Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state - Google Patents

Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state Download PDF

Info

Publication number
AU2015342969B2
AU2015342969B2 AU2015342969A AU2015342969A AU2015342969B2 AU 2015342969 B2 AU2015342969 B2 AU 2015342969B2 AU 2015342969 A AU2015342969 A AU 2015342969A AU 2015342969 A AU2015342969 A AU 2015342969A AU 2015342969 B2 AU2015342969 B2 AU 2015342969B2
Authority
AU
Australia
Prior art keywords
rapamycin
composition
synthetic nanocarriers
weight
carrier material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015342969A
Other languages
English (en)
Other versions
AU2015342969A1 (en
Inventor
David H. Altreuter
Aaron P. Griset
Conlin O'NEIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cartesian Therapeutics Inc
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of AU2015342969A1 publication Critical patent/AU2015342969A1/en
Application granted granted Critical
Publication of AU2015342969B2 publication Critical patent/AU2015342969B2/en
Priority to AU2021209204A priority Critical patent/AU2021209204A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AU2015342969A 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state Active AU2015342969B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021209204A AU2021209204A1 (en) 2014-11-05 2021-07-27 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462075864P 2014-11-05 2014-11-05
US201462075866P 2014-11-05 2014-11-05
US62/075,866 2014-11-05
US62/075,864 2014-11-05
PCT/US2015/059350 WO2016073799A1 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021209204A Division AU2021209204A1 (en) 2014-11-05 2021-07-27 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Publications (2)

Publication Number Publication Date
AU2015342969A1 AU2015342969A1 (en) 2017-04-27
AU2015342969B2 true AU2015342969B2 (en) 2021-05-27

Family

ID=54697646

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015342969A Active AU2015342969B2 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
AU2015342968A Active AU2015342968B2 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
AU2021209202A Active AU2021209202B2 (en) 2014-11-05 2021-07-27 Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
AU2021209204A Abandoned AU2021209204A1 (en) 2014-11-05 2021-07-27 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2015342968A Active AU2015342968B2 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
AU2021209202A Active AU2021209202B2 (en) 2014-11-05 2021-07-27 Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
AU2021209204A Abandoned AU2021209204A1 (en) 2014-11-05 2021-07-27 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Country Status (23)

Country Link
US (3) US20160128986A1 (https=)
EP (6) EP4356910A3 (https=)
JP (5) JP6912377B2 (https=)
KR (2) KR102601922B1 (https=)
CN (5) CN107072964A (https=)
AU (4) AU2015342969B2 (https=)
BR (3) BR122021025344B1 (https=)
CA (2) CA2966852C (https=)
CY (1) CY1124418T1 (https=)
DK (4) DK3215192T3 (https=)
EA (2) EA201790977A1 (https=)
ES (4) ES2977259T3 (https=)
FI (2) FI3834823T3 (https=)
HR (1) HRP20210098T1 (https=)
HU (4) HUE054894T2 (https=)
IL (7) IL296246A (https=)
LT (1) LT3215133T (https=)
MX (4) MX386982B (https=)
PL (1) PL3215133T3 (https=)
PT (1) PT3215133T (https=)
RS (1) RS61359B1 (https=)
SI (1) SI3215133T1 (https=)
WO (2) WO2016073799A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
WO2015025538A1 (ja) * 2013-08-20 2015-02-26 サンノプコ株式会社 バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
JP6774591B2 (ja) * 2015-02-17 2020-10-28 サンノプコ株式会社 バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
WO2016176462A1 (en) 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
ES2986077T3 (es) 2016-03-11 2024-11-08 Cartesian Therapeutics Inc Formulaciones y dosis de uricasa pegilada
KR102341902B1 (ko) * 2016-09-09 2021-12-21 카오카부시키가이샤 디카르복실산 결정 및 그 제조 방법
JP2019533718A (ja) 2016-09-27 2019-11-21 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． がんの処置における使用のための組換え免疫毒素
US20180193482A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
JP2022518504A (ja) * 2019-01-24 2022-03-15 ジェネレーション バイオ カンパニー 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
EP4048269A1 (en) 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
US20210187081A1 (en) 2019-11-08 2021-06-24 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
KR20220146559A (ko) 2020-02-26 2022-11-01 셀렉타 바이오사이언시즈, 인크. 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물
AU2021236234A1 (en) * 2020-03-11 2022-10-06 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
EP4135693A1 (en) * 2020-04-14 2023-02-22 Selecta Biosciences, Inc. Methods and compositions for inducing autophagy
IL302539A (en) 2020-11-04 2023-07-01 Selecta Biosciences Inc Compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
KR102304785B1 (ko) 2021-03-26 2021-09-24 (주)진성티앤피 정밀광학기기의 부품 제조 방법
EP4319747A1 (en) 2021-04-09 2024-02-14 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN120813689A (zh) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
TWI877967B (zh) * 2023-12-28 2025-03-21 訊聯生物科技股份有限公司 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075072A2 (en) * 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
US20120276109A1 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
US20140212462A1 (en) * 2009-12-30 2014-07-31 Samyang Biopharmeceuticals Corporation POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY (as amended)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
JP4526708B2 (ja) * 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
AU2003270102B2 (en) 2002-08-23 2008-10-02 Medigene Ag Non-vesicular cationic lipid formulations
CN1886100A (zh) * 2003-11-14 2006-12-27 阿尔萨公司 基于表面活性剂的凝胶作为可注射的持续药物递送载体
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
AU2011303849A1 (en) * 2010-09-14 2013-04-04 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
WO2012059936A1 (en) * 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
JP2014532071A (ja) 2011-10-14 2014-12-04 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
TWI439288B (zh) * 2012-10-05 2014-06-01 Univ China Medical 藥用載體及其製備方法與用途
CN102871966B (zh) * 2012-10-19 2013-11-20 东南大学 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075072A2 (en) * 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
US20140212462A1 (en) * 2009-12-30 2014-07-31 Samyang Biopharmeceuticals Corporation POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY (as amended)
US20120276109A1 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins

Also Published As

Publication number Publication date
HUE066099T2 (hu) 2024-07-28
DK3834823T3 (da) 2024-04-08
EP4356910A3 (en) 2024-05-22
AU2021209204A1 (en) 2021-08-19
CN107072964A (zh) 2017-08-18
IL288609B2 (en) 2023-02-01
EP4356910A2 (en) 2024-04-24
US20250152561A1 (en) 2025-05-15
EP4360633A2 (en) 2024-05-01
FI3906918T3 (fi) 2024-04-04
HUE067697T2 (hu) 2024-11-28
JP2017533243A (ja) 2017-11-09
IL283699B (en) 2022-09-01
AU2021209202B2 (en) 2023-11-30
EA201790978A1 (ru) 2017-09-29
CA2966850A1 (en) 2016-05-12
HUE053094T2 (hu) 2021-06-28
CN113244191A (zh) 2021-08-13
AU2015342969A1 (en) 2017-04-27
KR20170081660A (ko) 2017-07-12
BR122021025344B1 (pt) 2024-02-20
IL295292A (en) 2022-10-01
IL288609B (en) 2022-10-01
CA2966850C (en) 2024-03-26
AU2015342968B2 (en) 2021-05-27
CN115212186A (zh) 2022-10-21
MX2017005903A (es) 2017-06-27
KR102656139B1 (ko) 2024-04-11
RS61359B1 (sr) 2021-02-26
ES2977158T3 (es) 2024-08-20
KR20170081659A (ko) 2017-07-12
AU2021209202A1 (en) 2021-08-19
IL288609A (en) 2022-02-01
EP3215133B1 (en) 2020-10-28
WO2016073799A9 (en) 2016-12-08
CN107072965A (zh) 2017-08-18
CN107072965B (zh) 2021-05-11
FI3834823T3 (fi) 2024-04-02
JP6912377B2 (ja) 2021-08-04
EP3834823A1 (en) 2021-06-16
DK3215192T3 (da) 2021-05-03
WO2016073799A1 (en) 2016-05-12
PT3215133T (pt) 2021-01-29
CA2966852A1 (en) 2016-05-12
CA2966852C (en) 2024-01-02
JP7218089B2 (ja) 2023-02-06
BR112017008499B1 (pt) 2023-10-03
IL295292B2 (en) 2024-10-01
LT3215133T (lt) 2021-02-25
EP3215192B1 (en) 2021-02-17
JP2022173236A (ja) 2022-11-18
BR112017008499A2 (pt) 2017-12-26
MX383295B (es) 2025-03-13
EP3834823B1 (en) 2024-01-03
EP3906918A1 (en) 2021-11-10
EP4360633A3 (en) 2024-05-22
AU2015342968A1 (en) 2017-04-27
SI3215133T1 (sl) 2021-07-30
HRP20210098T1 (hr) 2021-03-05
IL283699A (en) 2021-07-29
IL251622B (en) 2021-06-30
IL280518A (en) 2021-03-01
CY1124418T1 (el) 2022-07-22
MX2021012273A (es) 2021-11-12
IL251620A0 (en) 2017-06-29
HUE054894T2 (hu) 2021-10-28
IL251620B (en) 2021-02-28
IL295292B1 (en) 2024-06-01
ES2977259T3 (es) 2024-08-21
EA201790977A1 (ru) 2017-10-31
EP3215192A1 (en) 2017-09-13
ES2865375T3 (es) 2021-10-15
JP2023169893A (ja) 2023-11-30
IL296246A (en) 2022-11-01
BR112017008720A2 (pt) 2017-12-19
IL280518B (en) 2022-01-01
MX2017005904A (es) 2017-06-27
WO2016073798A1 (en) 2016-05-12
US20160128986A1 (en) 2016-05-12
JP7827412B2 (ja) 2026-03-10
DK3906918T3 (da) 2024-04-08
EP3906918B1 (en) 2024-01-03
MX386982B (es) 2025-03-19
IL251622A0 (en) 2017-06-29
EP3215133A1 (en) 2017-09-13
KR102601922B1 (ko) 2023-11-15
CN115212187A (zh) 2022-10-21
US20160128987A1 (en) 2016-05-12
PL3215133T3 (pl) 2021-06-14
MX2021006698A (es) 2021-07-07
EP3215192A4 (en) 2018-05-02
ES2846809T3 (es) 2021-07-29
JP2021143180A (ja) 2021-09-24
DK3215133T3 (da) 2021-02-01
JP2017537081A (ja) 2017-12-14

Similar Documents

Publication Publication Date Title
US20250152561A1 (en) Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
US20210308058A1 (en) Methods and compositions related to synthetic nanocarriers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)